Symbols

SOPH

Sophia Genetics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SOPH

Sophia Genetics Sa

A cloud-native software company in the healthcare space

Industry

Life Science Tools and Services

Established Date

03/18/2011

Listing Date

07/23/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

415

Fiscal Year Ends

12-31

Website

www.sophiagenetics.com

Security Type

Common stock

Office address

La Pièce 12, CH-1180 Rolle, Switzerland

Business

Introduction

Sophia Genetics SA was incorporated in Switzerland on March 18, 2011. The company is a cloud-native software technology company in the medical field, dedicated to building data-driven medical practices through its SOPHiA DDM platform. The platform analyzes complex multimodal data and provides insights into precision medicine in the fields of oncology, rare diseases, etc., serving hospitals, laboratories and biopharmaceutical companies around the world.

Company Financials

EPS

SOPH has released its 2025 Q4 earnings. EPS was reported at -0.28, versus the expected -0.22, missing expectations. The chart below visualizes how SOPH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SOPH has released its 2025 Q4 earnings report, with revenue of 21.71M, reflecting a YoY change of 22.41%, and net profit of -19.18M, showing a YoY change of -26.53%. The Sankey diagram below clearly presents SOPH's revenue sources and cost distribution.